Phillips J K, Spearing R L, Davies J M, Hay C R, Parry H, Nash J R, Cawley J C
Department of Haematology, Royal Liverpool Hospital, England, UK.
Cancer Chemother Pharmacol. 1990;27(2):161-3. doi: 10.1007/BF00689103.
A total of 15 patients with relapsed or resistant Hodgkin's disease were treated with a combination of etoposide (VP16), ifosfamide, mitozantrone and dexamethasone (VIM-D). The regime was well tolerated, the only major toxicity being myelosuppression. Complete remissions (CRs) were obtained in 4 patients and were maintained for 2, 4, 10 and 14 months. 10 subjects subsequently received an autologous bone marrow transplant with high-dose chemotherapy (ABMT). Previous exposure to VIM-D did not appear to predict for or prejudice the response to subsequent ABMT.
总共15例复发或难治性霍奇金病患者接受了依托泊苷（VP16）、异环磷酰胺、米托蒽醌和地塞米松联合治疗（VIM-D）。该方案耐受性良好，唯一的主要毒性是骨髓抑制。4例患者获得完全缓解（CR），缓解持续时间分别为2、4、10和14个月。随后10名受试者接受了高剂量化疗的自体骨髓移植（ABMT）。先前接受VIM-D治疗似乎并不能预测或影响后续ABMT的反应。
